PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 112 filers reported holding PMV PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,819 | +11.0% | 3,065 | +13.1% | 0.00% | – |
| Q2 2023 | $16,958 | -21.5% | 2,709 | -40.2% | 0.00% | – |
| Q1 2023 | $21,608 | +218.8% | 4,530 | +481.5% | 0.00% | – |
| Q4 2022 | $6,777 | -99.9% | 779 | -99.9% | 0.00% | -100.0% |
| Q3 2022 | $9,200,000 | -16.5% | 773,096 | +0.0% | 0.00% | 0.0% |
| Q2 2022 | $11,016,000 | +18.6% | 773,051 | +73.3% | 0.00% | 0.0% |
| Q1 2022 | $9,288,000 | -20.0% | 446,119 | -11.3% | 0.00% | 0.0% |
| Q4 2021 | $11,612,000 | -40.5% | 502,700 | -23.2% | 0.00% | -50.0% |
| Q3 2021 | $19,501,000 | +7.6% | 654,400 | +23.3% | 0.00% | +100.0% |
| Q2 2021 | $18,129,000 | +30.8% | 530,714 | +25.9% | 0.00% | 0.0% |
| Q1 2021 | $13,860,000 | -46.6% | 421,400 | -0.2% | 0.00% | -50.0% |
| Q4 2020 | $25,970,000 | +77.9% | 422,200 | +2.7% | 0.00% | +100.0% |
| Q3 2020 | $14,598,000 | – | 411,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |